Cancer in Pregnancy: Management Recommendations – SMFM & ACOG

Navigating a cancer diagnosis is profoundly challenging at any stage of life, but the complexities are significantly heightened when it occurs during pregnancy. Recent recommendations, developed through a collaborative effort between the Society for Maternal-Fetal Medicine (SMFM) and endorsed by the American College of Obstetricians and Gynecologists (ACOG), aim to provide a more standardized and informed approach to managing cancer in pregnant patients. These guidelines, published in the March issue of Pregnancy, represent a crucial step toward optimizing care for a uniquely vulnerable population.

Understanding the Scope of the New Guidance

Historically, managing cancer during pregnancy presented a significant dilemma for clinicians. Traditional oncological protocols often didn’t account for the physiological changes of pregnancy, and concerns about fetal safety frequently led to treatment delays or modifications that could compromise the mother’s prognosis. The new recommendations seek to address these gaps by offering a comprehensive framework for diagnosis, staging, and treatment across various cancer types. The SMFM Consult Series is designed to provide practical guidance based on the best available evidence, acknowledging the inherent uncertainties and the need for individualized care plans.

The guidance isn’t a rigid set of rules, but rather a toolkit for healthcare providers. It emphasizes a multidisciplinary approach, involving obstetricians, oncologists, maternal-fetal medicine specialists, and other relevant experts to collaboratively develop treatment strategies. This collaborative model is particularly important given the potential for interactions between cancer therapies and the physiological changes of pregnancy.

Who is Affected by These Recommendations?

These recommendations directly impact pregnant individuals diagnosed with cancer, as well as the healthcare professionals involved in their care. While cancer in pregnancy is relatively rare – estimates suggest it occurs in approximately 1 in 1,000 pregnancies – the stakes are exceptionally high. The most common cancers diagnosed during pregnancy are breast cancer, cervical cancer, melanoma, leukemia, and lymphoma. The guidance applies to all stages of pregnancy and encompasses a wide range of cancer types, though specific recommendations may vary depending on the type and stage of the disease.

It’s important to note that the recommendations are intended for use in resource-rich settings where access to specialized care is available. Implementation in areas with limited healthcare infrastructure may present challenges. The SMFM and ACOG recognize this disparity and are working to develop resources to support implementation in diverse settings.

Evidence and Limitations: A Nuanced Approach

The development of these recommendations involved a rigorous review of the existing literature, including observational studies, case reports, and expert opinion. However, the evidence base for managing cancer in pregnancy remains limited due to the rarity of the condition and the ethical challenges of conducting randomized controlled trials in this population. Many treatment decisions are therefore based on extrapolation from non-pregnant populations and careful consideration of potential risks, and benefits.

A key limitation is the lack of long-term data on the effects of cancer treatment on both the mother and the child. While short-term outcomes are relatively well-studied, the potential for late effects, such as developmental delays or increased risk of secondary cancers, remains a concern. The recommendations acknowledge this uncertainty and emphasize the importance of long-term follow-up for both mother and child. Further research is needed to address these knowledge gaps and refine treatment strategies. You can find more information about cancer research at the National Cancer Institute: https://www.cancer.gov/

Navigating Treatment Options During Pregnancy

The guidance addresses various treatment modalities, including surgery, chemotherapy, and radiation therapy. The feasibility and safety of each approach depend on the specific cancer type, stage of pregnancy, and individual patient factors. For example, surgery may be preferred in certain cases to avoid exposing the fetus to chemotherapy or radiation. However, surgical interventions also carry risks, such as preterm labor.

Chemotherapy regimens are often modified during pregnancy to minimize fetal exposure. Timing is crucial; certain chemotherapy agents are considered relatively safe during specific trimesters, while others should be avoided altogether. Radiation therapy is generally avoided during pregnancy due to the potential for teratogenic effects (birth defects). However, in some cases, radiation may be considered after the first trimester if the benefits outweigh the risks.

What Does This Mean for Pregnant Patients?

For pregnant patients facing a cancer diagnosis, these recommendations offer a sense of hope and reassurance. They signify a growing recognition of the unique challenges they face and a commitment to providing evidence-based, compassionate care. The emphasis on multidisciplinary collaboration ensures that treatment decisions are made in the context of both maternal and fetal well-being.

However, it’s crucial to understand that these recommendations are not a substitute for individualized medical advice. Every patient’s situation is unique, and treatment plans should be tailored accordingly. Open communication with your healthcare team is essential to ensure that you understand the risks and benefits of all available options.

The Public Health Process: Continuous Improvement

The development of these recommendations is not a one-time event, but rather an ongoing process. The SMFM and ACOG will continue to monitor the literature, gather data, and refine the guidance as new evidence emerges. Regular updates will be published to reflect the latest advances in cancer care and maternal-fetal medicine. The ASCO Post also reported on the SMFM guidance: https://news.google.com/rss/articles/CBMiwAFBVV95cUxPQXVTbXBVTFhNZ1lac0IybDZTUy1TRjJVeTBWOHlSVURaQUlZandGYktCaWtKQUVaNEJQWDhXOG44cDV0RHhjRlFxcWxJbVFiZUV0ZTFWTzVJVGFJQVdqUm1oeDBCSUNmeHkyQzV3UkR1ZVVLV3hDNERDVU51MnRwOFVMdjBDQXNHQzFLbHV0RktYc3NfbVNOaUVZandJVkN2TndfWURFM0l3ajlTVEZabjNJQVU2X2ZNSF9DVWhWSEc?oc=5

ongoing surveillance efforts are crucial to identify trends in cancer incidence and outcomes during pregnancy. Data from cancer registries and other sources can help to inform public health interventions and improve the quality of care. The New Jersey Department of Health also recently issued reminders about vaccinations and prenatal care: https://news.google.com/rss/articles/CBMibEFVX3lxTE1aOUt4cVc3ams4LUlIQk9LRmFPNDc1d1BSWFVrbFNrcGxEMTJwcnpZYzBfSExPN2h2ZXhIcVpBRWtjSXlNT3IwRWxmRW5MaE9uZ1NFNE5SRVB1QVRhM3BieDRhVUhsZUdoQUVTcA?oc=5

What to Expect Moving Forward: The SMFM and ACOG plan to convene expert panels to review the recommendations periodically, incorporating new research findings and addressing emerging challenges. They also intend to develop educational materials for both healthcare professionals and patients to promote awareness and facilitate implementation of the guidance. ACOG also has recommendations for managing cancer in pregnancy: https://news.google.com/rss/articles/CBMic0FVX3lxTE1CM0E3VnE4Q2dqOXFWS1JwdG56NlRzYzN1VmJrRTdrdVBHcmNvNVZPU21uWFM0LWFuQm9QR2VTWlJMX3Z4QlBYSm5xbkxYQVlmVWFiMGZpbjRWdnF3d2pfVzI0QkJubEh2OG5rWVhzR3p5VDA?oc=5